Catalog No.
Product Name
Application
Product Information
Citations
-
Inhibitor of PD-1/PD-L1 Protein-Protein Interaction
LH1307 is a C2-symmetric inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 value of 3.0 μM. This compound serves as a valuable tool for cancer research, enabling the exploration of immunotherapeutic strategies targeting the PD-1/PD-L1 axis. Its application can facilitate studies on immune evasion mechanisms in tumors and the development of novel cancer therapies. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-13 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM. This compound effectively promotes CD8+ T cell activation, enhancing anti-tumor immunity. Its application in preclinical models, such as the Hepa1-6 syngeneic mouse model, demonstrates its potential to delay tumor growth, making it valuable for research in immunotherapy and cancer biology. -
hPD-1/hPD-L1 Interaction Inhibitor
Human PD-L1 inhibitor V is a peptide that specifically targets the interaction between human PD-1 and PD-L1, exhibiting a binding affinity characterized by a Kd value of 3.32 μM. This inhibitor is valuable for research applications focused on immune checkpoint modulation and cancer immunotherapy, as it effectively disrupts the PD-1/PD-L1 signaling pathway, which is critical in the regulation of immune responses. -
PD-L1 Inhibitor
Human PD-L1 Inhibitor IV is a competitive inhibitor of the human PD-1 protein, exhibiting a Kd value of 1.38 μM. This polypeptide effectively disrupts the interaction between human PD-1 and PD-L1, facilitating research into immune checkpoint pathways. It is applicable for studies focused on cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
IMMH-010 maleate is a prodrug that functions as a PD-L1 inhibitor, demonstrating significant potential for antitumor activity in neurological disorders and advanced malignant solid tumors. Upon oral administration, IMMH-010 maleate is swiftly converted to its active form, YPD-29B. This compound is designed to facilitate research in the area of PD-L1 inhibition and its therapeutic implications. -
PD-1 Inhibitor
PD1-PDL1-IN 1 is a potent inhibitor of programmed cell death 1 (PD-1), a critical checkpoint in immune regulation. This compound serves as an immune modulator, facilitating enhanced T-cell activation and proliferation. PD1-PDL1-IN 1 is valuable for research applications focused on cancer immunotherapy and elucidating immune response mechanisms. -
PD-1/PD-L1 Inhibitor
Human PD-L1 inhibitor II is a potent inhibitor of the PD-1/PD-L1 interaction, playing a crucial role in immune checkpoint regulation. This compound exhibits significant anti-cancer activity by enhancing T-cell responses against tumor cells. It is primarily used in research applications focused on cancer immunotherapy and understanding the mechanisms of immune evasion. -
PD-L1 PROTAC Degrader
PROTAC PD-L1 degrader-2 is a selective degrader targeting PD-L1. It demonstrates a potent inhibitory effect with an IC50 of 197.4 nM and a binding affinity characterized by a Kd of 301 nM. This compound facilitates the internalization and subsequent degradation of PD-L1 through both proteasomal and lysosomal pathways, thereby enhancing immune system activation. Its efficacy has been validated in MC38 C57BL/6 mouse models, underscoring its potential for antitumor applications. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-36 is an inhibitor of the PD-1/PD-L1 complex, exhibiting an IC50 of 15 nM. This compound plays a crucial role in cancer immunotherapy research by blocking the interaction between PD-1 and PD-L1, which is instrumental in tumor immune evasion. Its application in studies may enhance understanding of immune checkpoint mechanisms and the development of novel therapeutic strategies in oncology. -
PD-1/PD-L1Inhibitor
SCL-1 is an orally active inhibitor of the PD-1/PD-L1 pathway, effectively blocking the interaction between PD-1 and PD-L1. This compound enhances the proliferation of T cells, B cells, and natural killer cells, contributing to robust antitumor activity. SCL-1 mediates tumor growth inhibition through the induction of effector T cells within the tumor environment and by upregulating long non-coding RNAs that act as neoantigens, facilitating cytotoxic T lymphocyte activation. This reagent is valuable for cancer research, particularly in studies focused on triple-negative breast cancer. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN 5 is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of ≤100 nM. This compound is valuable for studies investigating immune checkpoint inhibition and its role in enhancing anti-tumor immunity. Researchers can utilize this reagent in various applications related to cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN 5 TFA is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, with an IC50 of ≤100 nM. This compound is beneficial for research applications focused on immune checkpoint modulation, particularly in the context of cancer immunotherapy. By blocking the PD-1/PD-L1 pathway, it aids in the investigation of T-cell activation and tumor immune evasion mechanisms. -
hPD-1 Ligand
Human PD-L1 inhibitor I is a peptide ligand targeting human PD-1 ligand with a binding affinity (KD) of 3.39 μM. This compound is designed to disrupt the interaction between hPD-L1 and hPD-1, making it a valuable tool for studying immune checkpoint inhibition. Its applications include investigating mechanisms of immune evasion in cancer and exploring potential therapeutic strategies for enhancing anti-tumor immunity. -
PD-1/PD-L1 Inhibitor
LLW-018 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 value of 2.61 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, showing an IC50 of 0.88 μM in cell-based assays. LLW-018 holds significant potential for applications in immunotherapy research, particularly in the development of cancer treatments that target immune checkpoint pathways. -
PD-1/PD-L1 inhibitor
PD-1/PD-L1-IN 6 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 value of 132.8 nM. This compound exhibits significant immunoregulatory activity, notably enhancing interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, while exhibiting minimal toxicity. Additionally, PD-1/PD-L1-IN 6 is effective in restoring immune responses in T cell-tumor co-culture models, making it a valuable reagent for immunotherapy research and studies related to cancer immunology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-32 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 of 2.4 nM. This compound demonstrates significant anticancer activity by effectively inhibiting tumor growth in a humanized mouse model expressing PD-L1. Importantly, PD-1/PD-L1-IN-32 exhibits limited toxicity on normal mouse tissues, making it a valuable tool for cancer research and therapeutic applications targeting immune checkpoint pathways. -
PD-L1 Inhibitor
BMS-1233 is a potent inhibitor of programmed cell death-ligand 1 (PD-L1) with an IC50 of 14.5 nM. This compound promotes cytotoxicity in HepG2 cells within a Jurkat T cell and HepG2 co-culture model, demonstrating significant antitumor activity against melanoma in in vivo mouse models. BMS-1233 is suitable for research applications focused on cancer immunotherapy and the modulation of immune checkpoint pathways. -
PD-L1 Ligand
2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a ligand for PD-L1, playing a crucial role in the development of AUTAC PD-L1 degrader-3. This compound is essential for facilitating targeted degradation of PD-L1, making it a valuable tool in cancer immunotherapy research and studies focusing on the modulation of immune checkpoints. Additionally, it can be utilized in the synthesis of AUTACs for advanced therapeutic applications. -
PD-L1/NAMPT Inhibitor
PD-L1/Nampt-IN-1 is a dual inhibitor targeting PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50 values of 63 nM and 582 nM, respectively. This compound exhibits cross-species affinity with comparable KD values for human PD-L1 (52.6 nM) and mouse PD-L1 (49.1 nM). PD-L1/Nampt-IN-1 facilitates tumor growth inhibition by enhancing the tumor immune microenvironment, making it a valuable tool for research in melanoma studies. -
PD-1/PD-L1 Inhibitor
LP23 is a potent non-arylmethylamine inhibitor of the PD-1/PD-L1 axis, exhibiting an IC50 of 16.7 nM. It effectively restores immune cell function in HepG2 and Jurkat T cell assays and promotes cell death in HepG2 cancer cells. In vivo studies demonstrate its significant anti-tumor activity in the B16-F10 tumor model, achieving a tumor growth inhibition of 88.6% at a dose of 30 mg/kg. This compound serves as a valuable tool for cancer immunotherapy research and the investigation of immune checkpoint pathways. -
PD-L1 Inhibitor
PD-L1-IN-5 is a potent inhibitor of programmed death-ligand 1 (PD-L1), exhibiting an IC50 value of 785.6 nM. This compound demonstrates significant anti-tumor activity in vivo, making it a valuable tool for cancer research. PD-L1-IN-5 is utilized in studies focusing on immune checkpoint regulation and therapeutic strategies aimed at enhancing anti-tumor immunity. -
PD-L1
Cadapersen is an antisense oligonucleotide that selectively induces the degradation of PD-L1 mRNA. By inhibiting PD-L1 expression, this reagent serves as a valuable tool in the investigation of immune responses and mechanisms underlying chronic hepatitis B (CHB). Its application in research enhances the understanding of immune checkpoint regulation, facilitating studies geared towards novel therapeutic strategies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-26 is a potent inhibitor of the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, exhibiting an IC50 of 0.0380 μM. This compound enhances the immune microenvironment by facilitating the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 is valuable for research applications focused on cancer immunotherapy and the modulation of immune responses in tumor biology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-59 is a PD-1/PD-L1 inhibitor with an IC50 value of 183 nM. This compound is instrumental in the investigation of immune checkpoint regulation and has significant potential for research applications in triple-negative breast cancer (TNBC) therapies. By blocking the PD-1/PD-L1 interaction, it fosters immune response against tumor cells and facilitates the exploration of novel immunotherapeutic strategies. -
PD-L1 Inhibitor
PD-1/PD-L1-IN-60 is an inhibitor of PD-L1, a key checkpoint protein involved in immune evasion of tumors. This compound demonstrates significant anti-tumor activity in preclinical models, particularly within melanoma and lung cancer contexts where PD-L1 expression is elevated. PD-1/PD-L1-IN-60 is suitable for research applications focused on immunotherapy, tumor immune microenvironment studies, and the evaluation of therapeutic strategies targeting PD-L1. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-20 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 5.29 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, making it a valuable tool for research in oncology, infectious diseases, and autoimmune disorders. Its ability to modulate immune checkpoint proteins provides significant insights into therapeutic strategies for enhancing anti-tumor immunity. -
PD-L1 Enhancer
Ir-UA is an iridium(III) complex derived from usnic acid that serves as a PD-L1 enhancer. This compound promotes the expression of PD-L1 by specifically modulating the associated transcription factors, thus facilitating the conversion of "cold tumors" into "hot tumors." Ir-UA is valuable in cancer research, particularly in studies focused on immunotherapy and tumor microenvironment modulation. -
PD-L1/PD-1 Inhibitor
PD-L1/PD-1-IN-1 is a potent inhibitor of the PD-L1/PD-1 interaction, demonstrating an IC50 of less than 1 nM. This compound is significant for research in anti-tumor therapies, facilitating the study of immune checkpoint modulation and its effects on tumor growth. Its ability to effectively block PD-L1 signaling makes it a valuable tool for exploring therapeutic strategies in cancer immunotherapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-19 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 of 62.3 nM, it effectively inhibits the binding of PD-1 to PD-L1, thereby modulating immune responses. This compound is suitable for research applications in cancer immunotherapy, as well as studies focused on infectious and autoimmune diseases. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-17 is a potent inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 26.8 nM. This compound serves as a valuable lead in the development of PD-1/PD-L1 inhibitors, making it an important tool for cancer research. Its ability to modulate immune checkpoint pathways highlights its potential in the exploration of cancer immunotherapy strategies. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-1 is a potent inhibitor of PD-1/PD-L1 interactions, demonstrating EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization. This compound is essential for investigating the role of immune checkpoint modulation in hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Its ability to enhance T cell responses makes it valuable for research in immunotherapy and viral pathogenesis. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-52 is an orally bioavailable inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 109.9 nM. This compound exhibits significant antitumor effects, as evidenced by a tumor growth inhibition (TGI) of 49.6% in a C57BL/6 mouse xenograft model utilizing human PD-1-expressing MC38 colon cancer cells. Research applications include the exploration of immune checkpoint modulation and therapeutic strategies in cancer treatment. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-31 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 2.2 nM. This compound enhances the secretion of interferon-gamma (IFN-γ) and stimulates the immune response of peripheral blood mononuclear cells (PBMCs), leading to the inhibition of tumor cell proliferation. PD-1/PD-L1-IN-31 is valuable for research applications focused on cancer immunotherapy and the modulation of immune checkpoints. -
PD-1/PD-L1 Inhibitor
PD-1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM as determined by HTRF assay. This compound enhances CD8+ T cell activation by disrupting PD-1/PD-L1 signaling pathways. PD-1-IN-25 demonstrates significant potential for delaying tumor growth, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
BMS-242 is a small molecule inhibitor targeting the PD-1/PD-L1 interaction. It effectively binds to the hydrophobic channel pocket of PD-L1, disrupting the PD-1/PD-L1 immune checkpoint pathway. This action enhances anti-tumor immunity, making BMS-242 a valuable tool for cancer research and therapeutic studies focused on immune modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-24 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 1.57 nM. This compound effectively restores T-cell function by significantly increasing the levels of IFN-γ at the cellular level. With low toxicity towards peripheral blood mononuclear cells (PBMCs), PD-1/PD-L1-IN-24 is suitable for research applications focused on cancer immunotherapy and autoimmunity studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-21 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 4.99 μM. This compound effectively blocks PD-1 and PD-L1, making it a valuable tool for research into cancer, infectious diseases, and autoimmune conditions. Its ability to disrupt this immune checkpoint pathway positions PD-1/PD-L1-IN-21 as a significant reagent for studies aimed at enhancing anti-tumor immunity and understanding immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-53 is a potent inhibitor of the PD-1/PD-L1 and VISTA signaling pathways. This compound is primarily utilized in anti-cancer research to investigate immune checkpoint mechanisms and enhance T-cell activation. PD-1/PD-L1-IN-53 provides valuable insights for studies focused on tumor microenvironments and immunotherapy responses. -
PD-L1/VISTA Inhibitor
PD-L1/VISTA-IN-1 is a potent dual-target inhibitor of programmed death ligand 1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA). This compound effectively disrupts the PD-1/PD-L1 interaction with an IC50 of 0.1492 μM and inhibits the VISTA pathway with a KD of 0.2723 μM, promoting T cell reactivation. PD-L1/VISTA-IN-1 demonstrates significant anti-tumor activity, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-2 is a potent inhibitor of both hepatitis B virus (HBV) and hepatitis D virus (HDV), as well as the PD-1/PD-L1 pathway. It exhibits an EC50 of 35 nM for T cell activation, making it a valuable tool for investigating immune modulation in viral infections. This compound is applicable in research aimed at understanding the interplay between viral infections and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-55 is a potent inhibitor targeting the PD-1/PD-L1 immune checkpoint pathway, exhibiting an IC50 of 4.8 nM. This compound enhances the secretion of IFN-γ and decreases the incidence of late apoptosis in PD-L1 expressing cells. PD-1/PD-L1-IN-55 is valuable for research applications in cancer therapy and immunology, particularly in studies aimed at restoring T-cell activation and modulating immune responses. -
PDCD1/PD-1/CD279 Antibody
Liscastobart is a humanized IgG4κ antibody that specifically targets the programmed cell death protein 1 (PDCD1/PD-1/CD279). This antibody is instrumental in studies aimed at understanding immune regulation and checkpoint inhibition, making it valuable for cancer immunotherapy research. Its application includes assessing PD-1 blockade effects in various in vitro and in vivo models. -
PD-1/PD-L1 Inhibitor
PD1-PDL1-IN 2 is a potent and selective inhibitor of the PD-1/PD-L1 pathway. This compound demonstrates significant antitumor activity in vivo by promoting cytotoxic T-cell infiltration into tumors and inducing interleukin-2 (IL-2) expression. Additionally, PD1-PDL1-IN 2 strongly inhibits the mRNA expression of TGF-β, making it a valuable tool for research in cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
PD-L1-IN-7 is a potent inhibitor of programmed cell death ligand 1 (PD-L1), effectively disrupting the PD-1/PD-L1 interaction with an IC50 of 0.2 nM. This compound facilitates the internalization and retention of PD-L1 within cells, alters glycosylation patterns, and promotes PD-L1 degradation. PD-L1-IN-7 enhances T cell infiltration and boosts T cell cytotoxic function, making it a valuable tool for developing immunotherapeutic strategies against tumors. -
PD-1/PD-L1 Inhibitor
Human PD-L1 Inhibitor III is a selective inhibitor targeting the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. By blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, this compound enhances T-cell activity, promoting anti-tumor immune responses. It is valuable for researchers investigating cancer immunotherapy and assessing therapeutic strategies aimed at modulating immune checkpoint pathways. -
PD-L1 Binding Peptide
RK-10 is a PD-L1 binding peptide that specifically targets programmed death-ligand 1 (PD-L1). This peptide can be conjugated with fluorescent dyes such as Cy5 or biotin for the detection of PD-L1 expressing tumors via flow cytometry or immunohistochemistry. RK-10 serves as a valuable tool for research applications related to non-small cell lung cancer (NSCLC), breast cancer, squamous cell carcinoma, and melanoma, facilitating studies on tumor immunology and therapeutic responses. -
PD-L1 Inhibitor
PD-L1-IN-4 is a selective inhibitor of PD-L1, demonstrating potent inhibition of the PD-1/PD-L1 interaction with an IC50 value of 1.3 nM. This compound also enhances the PD-L1 inhibitory effect on T cells, with an EC50 of 152.8 nM. PD-L1-IN-4 is suitable for studies in cancer research, particularly in the context of immunotherapy and tumor microenvironment modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-27 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 134 nM. This compound exhibits significant antitumor activity while maintaining low cytotoxicity towards T cells. Additionally, PD-1/PD-L1-IN-27 effectively activates CD8+ T cells and mitigates T cell exhaustion, making it a valuable tool for immuno-oncology research applications. -
PD-1/PD-L1 Inhibior
PD-1/PD-L1-IN-47 is a potent inhibitor of the PD-1/PD-L1 signaling pathway, selectively targeting PD-L1 under acidic conditions. This compound demonstrates significant affinity for its target while exhibiting reduced toxicity, making it a valuable tool in cancer research. PD-1/PD-L1-IN-47 is ideally suited for studies focused on tumor microenvironments and immune modulation in various cancer types. -
PD-1/PD-L1 Inhibitor
SWS1 is a d-(+)-biotin-conjugated inhibitor of PD-L1 with an IC50 of 1.8 nM. It has demonstrated significant anticancer activity by enhancing tumor-infiltrating lymphocyte populations and inducing anti-tumor effects in the B16-F10 mouse model, achieving a tumor growth inhibition rate of 66.1%. SWS1 is suitable for research applications focused on immunotherapy and tumor microenvironment studies.
